GHAPPcast

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • 0,0 (0)
  • MEDICINA

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).   Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

  1. HACE 5 D

    FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?

    Thank you AbbVie for your support on this FAQ Video Module. In this FAQ video module, Jamie Brogan, APRN from the IBD Center at Northwestern Medicine, breaks down the October 2025 FDA label expansion for upadacitinib in adult patients with moderate to severely active ulcerative colitis and Crohn’s disease. The discussion focuses on the updated indication for patients with an inadequate response or intolerance to TNF inhibitors—and importantly, the newly emphasized language around when TNF therapy may be considered “clinically inadvisable.” Jamie explores what this term means in real-world clinical practice, including patient-specific factors such as contraindications to TNF agents, need for rapid onset of action, prior treatment exposure, comorbidities, and access or adherence challenges. She shares practical insights on how this label expansion has impacted IBD management, increased treatment access, and supported individualized, risk-benefit decision-making between providers and patients.

    4 min

  2. 27 ENE

    FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?

    Thank you Madrigal for your support on this FAQ Video Module. In this FAQ video, Allysa Saggese, NP, reviews how clinicians can balance systemic and liver-directed therapies in the treatment of metabolic dysfunction–associated steatohepatitis (MASH) and shares insights on the evolving role of combination therapy. The discussion explores current guideline-aligned options, including GLP-1–based systemic therapies and liver-directed agents, and emphasizes individualized treatment decisions based on fibrosis stage, metabolic comorbidities, patient preferences, and access considerations. Designed for APPs and clinicians, this overview highlights why multimodal therapy—alongside lifestyle interventions like diet and exercise—is likely the future of MASH management.

    3 min

  3. 20 ENE

    FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?

    Thank you Madrigal for your support of this FAQ Video Module. In this FAQ video, Alison Moe, PA-C, discusses how alcohol consumption impacts the evaluation and progression of metabolic dysfunction–associated steatohepatitis (MASH) and why accurate assessment is critical in clinical practice. The discussion reviews the synergistic effects of alcohol and metabolic liver disease on fibrosis progression, explains current alcohol intake thresholds associated with increased risk, and outlines how biomarkers such as phosphatidylethanol (PEth) can provide objective insight into recent alcohol use. Designed for APPs and clinicians, this practical overview highlights how to differentiate MASH, alcohol-related liver disease (ALD), and MetALD to ensure accurate diagnosis, documentation, and treatment decisions.

    6 min

  4. 13 ENE

    Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment

    Thank you Madrigal for your support of this Medication Review Video Module. In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2–F3). The discussion reviews MASH risk factors, resmetirom’s mechanism of action, dosing considerations, and key findings from the phase 3 MAESTRO-NASH trial, including improvements in liver histology and lipid parameters. Designed for APPs and clinicians, this concise review highlights how resmetirom fits into contemporary MASH management alongside lifestyle interventions such as diet and exercise.

    5 min

  5. 8 ENE

    APP Roundtable: Approach To Starting Treatments in Patients With CHB

    In this expert-led podcast discussion on hepatitis B management, Elizabeth Goacher, PA-C, from Duke University Medical Center and Allison Moser, NP, from RUSH University Medical Center break down what’s new in chronic hepatitis B care and how evolving guidelines are shaping real-world clinical decision-making. Recorded onsite at GHAPP National, the conversation explores updated treatment thresholds from European Association for the Study of the Liver compared with American Association for the Study of Liver Diseases, including when to initiate antiviral therapy regardless of HBeAg status, the role of HBV DNA and ALT levels, and special considerations such as pregnancy, renal and bone health, adherence, and HIV co-infection. The episode also highlights practical antiviral selection, patient-centered counseling, risks of treatment interruption, and emerging therapies aimed at functional cure. This discussion offers timely, practice-focused insights for APPs and clinicians caring for patients with hepatitis B.

    13 min

  6. 7 ENE

    APP Roundtable: Navigating Difficult Conversations in CHB

    This in-depth conversation explores how advanced practice providers navigate some of the most challenging discussions in the care of patients living with chronic hepatitis B. Drawing from years of real-world hepatology and transplant experience, Jennifer Geremia, PA-C, and Andrea Keller, PA, discuss culturally sensitive communication, addressing stigma, improving health literacy, and building trust with patients and families affected by hepatitis B. The discussion highlights practical strategies for long-term disease management, medication adherence, family screening and vaccination, perinatal transmission counseling, and the importance of regular monitoring to prevent cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The speakers also address common misconceptions, language barriers, and shared decision-making, offering actionable insights for APPs and clinicians caring for diverse hepatitis B populations. #Hepatology #LiverDisease #ChronicHepatitisB #AdvancedPracticeProviders #GHAPP #TransplantHepatology #PatientCommunication #CulturalCompetency #HealthLiteracy #LiverCare #ChronicDiseaseManagement

    25 min

  7. 6 ENE

    APP Roundtable: Addressing Co-Morbidities in CHB

    In this expert-led podcast discussion, Patrick Horne and HoChong Gilles explore the complex management of comorbidities in patients with chronic viral hepatitis, with a focus on hepatitis B, hepatitis C, and HIV co-infection. The conversation highlights practical strategies for treatment sequencing, preventing hepatitis B reactivation during DAA therapy, managing drug–drug interactions, and optimizing long-term liver and systemic outcomes. The episode also examines the growing impact of metabolic dysfunction–associated steatotic liver disease (MASLD/MASH) on fibrosis progression and hepatocellular carcinoma (HCC) risk, along with current surveillance approaches including ultrasound and AFP. Additional insights address renal and bone health considerations with long-term hepatitis B antiviral therapy and the importance of multidisciplinary, whole-patient care when managing cardiovascular, metabolic, and renal co-morbidities in this high-risk population. Visit the GHAPP Digital Hub, Hep B Health Hub or GHAPP ACE app for more educational content.

    20 min

  8. 6 ENE

    FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?

    Thank you Madrigal for your support on this FAQ Video Module. In this short FAQ video module, Patrick Horne, President of GHAPP and a nurse practitioner at the University of Florida, discusses the critical role of noninvasive tests (NITs) in risk stratification and patient selection for patients with metabolic dysfunction–associated steatohepatitis (MASH). He explains how serum biomarkers and imaging help establish baseline fibrosis, clarify disease severity, and guide clinical decision-making in a condition with variable and non-linear progression. This overview emphasizes the importance of integrating NITs with a thorough patient history and physical exam to better understand fibrosis stage and optimize patient evaluation. Visit the GHAPP Digital Hub or GHAPP ACE 2.0 app for more gastroenterology and hepatology education.

    2 min
Ver todo (137)

Información

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).   Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Ficha técnica

  • Creado por
    Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • Años en activo
    2023 - 2026
  • Episodios
    137
  • Clasificación
    Apto
  • Derechos de autor
    © 2025 GHAPPcast
  • Sitio web del podcast
    GHAPPcast

Quizá también te guste